Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Hypomorphic GINS3 variants alter DNA replication and cause Meier-Gorlin syndrome
Mary E. McQuaid, Kashif Ahmed, Stephanie Tran, Justine Rousseau, Ranad Shaheen, Kristin D. Kernohan, Kyoko E. Yuki, Prerna Grover, Dominique Lévesque, Ema S. Dreseris, Sameen Ahmed, Lucie Dupuis, Jennifer Stimec, Mary Shago, Zuhair N. Al-Hassnan, Roch Tremblay, Philipp G. Maass, Michael D. Wilson, Eyal Grunebaum, Kym M. Boycott, François-Michel Boisvert, Sateesh Maddirevula, Eissa A. Faqeih, Fahad Almanjomi, Zaheer Ullah Khan, Fowzan S. Alkuraya, Philippe M. Campeau, Peter Kannu, Eric I. Campos, Hugo Wurtele
Mary E. McQuaid, Kashif Ahmed, Stephanie Tran, Justine Rousseau, Ranad Shaheen, Kristin D. Kernohan, Kyoko E. Yuki, Prerna Grover, Dominique Lévesque, Ema S. Dreseris, Sameen Ahmed, Lucie Dupuis, Jennifer Stimec, Mary Shago, Zuhair N. Al-Hassnan, Roch Tremblay, Philipp G. Maass, Michael D. Wilson, Eyal Grunebaum, Kym M. Boycott, François-Michel Boisvert, Sateesh Maddirevula, Eissa A. Faqeih, Fahad Almanjomi, Zaheer Ullah Khan, Fowzan S. Alkuraya, Philippe M. Campeau, Peter Kannu, Eric I. Campos, Hugo Wurtele
View: Text | PDF
Research Article Cell biology

Hypomorphic GINS3 variants alter DNA replication and cause Meier-Gorlin syndrome

  • Text
  • PDF
Abstract

The eukaryotic CDC45/MCM2-7/GINS (CMG) helicase unwinds the DNA double helix during DNA replication. The GINS subcomplex is required for helicase activity and is, therefore, essential for DNA replication and cell viability. Here, we report the identification of 7 individuals from 5 unrelated families presenting with a Meier-Gorlin syndrome–like (MGS-like) phenotype associated with hypomorphic variants of GINS3, a gene not previously associated with this syndrome. We found that MGS-associated GINS3 variants affecting aspartic acid 24 (D24) compromised cell proliferation and caused accumulation of cells in S phase. These variants shortened the protein half-life, altered key protein interactions at the replisome, and negatively influenced DNA replication fork progression. Yeast expressing MGS-associated variants of PSF3 (the yeast GINS3 ortholog) also displayed impaired growth, S phase progression defects, and decreased Psf3 protein stability. We further showed that mouse embryos homozygous for a D24 variant presented intrauterine growth retardation and did not survive to birth, and that fibroblasts derived from these embryos displayed accelerated cellular senescence. Taken together, our findings implicate GINS3 in the pathogenesis of MGS and support the notion that hypomorphic variants identified in this gene impaired cell and organismal growth by compromising DNA replication.

Authors

Mary E. McQuaid, Kashif Ahmed, Stephanie Tran, Justine Rousseau, Ranad Shaheen, Kristin D. Kernohan, Kyoko E. Yuki, Prerna Grover, Dominique Lévesque, Ema S. Dreseris, Sameen Ahmed, Lucie Dupuis, Jennifer Stimec, Mary Shago, Zuhair N. Al-Hassnan, Roch Tremblay, Philipp G. Maass, Michael D. Wilson, Eyal Grunebaum, Kym M. Boycott, François-Michel Boisvert, Sateesh Maddirevula, Eissa A. Faqeih, Fahad Almanjomi, Zaheer Ullah Khan, Fowzan S. Alkuraya, Philippe M. Campeau, Peter Kannu, Eric I. Campos, Hugo Wurtele

×

Figure 6

Yeast models expressing GINS3 D24G or D24N variants present defects in cell growth and protein stability.

Options: View larger image (or click on image) Download as PowerPoint
Yeast models expressing GINS3 D24G or D24N variants present defects in c...
(A) Structural alignments of human GINS3 (PDB entry 2Q9Q) and yeast Psf3 (PDB entry 5U8S) proteins. A view down helix 1 (left) and a side view of helix 1 (right) are shown. Human GINS3 is in cyan, with residue D24 in ice blue; yeast Psf3 is in red, with residue D8 in orange. (B) Cell population doubling time, as measured by monitoring OD630 of 8 cultures of each genotype during exponential growth. Results are representative of 3 independent experiments, and statistical analyses were performed using 2-tailed t tests. (C) Cell cycle profiles of asynchronously growing (AS) cultures were assessed by flow cytometry. The experiment was performed twice; a representative replicate is shown. (D) Cells were synchronized in G1 by α factor arrest and were then released into S phase. Samples were fixed every 10 minutes after release and cell cycle progression assessed by flow cytometry. The experiment was performed in duplicate; a representative replicate is shown. (E) Serial 5-fold dilutions of yeast were grown on solid media in the presence or absence of nicotinamide (NAM) at 30°C for 72 hours. The experiment was performed in duplicate; a representative replicate is shown. (F) Exponentially growing yeast cultures were treated with 100 μg/mL cycloheximide (CHX). Samples were removed for protein extraction at the indicated times after CHX addition. Psf3 protein levels were assessed by immunoblotting. A representative blot is shown, and the results from 3 biological replicates are summarized in the graph. For details on experimental procedures, see Methods. P values were adjusted for multiple comparisons where appropriate (see Methods). *P < 0.05, **P < 0.01

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts